Apr 25, 2018   SOURCE: PR NewsWire

Global In-Vitro Diagnostics/IVD Market 2018-2023: Increasing Adoption of Fully Automated Instruments and Automation in Laboratories

Global In-Vitro Diagnostics/IVD Market 2018-2023: Increasing Adoption of Fully Automated Instruments and Automation in Laboratories

DUBLIN, April 25, 2018 /PRNewswire/ --

The "In Vitro Diagnostics/IVD Market by Product (Instruments, Reagents), Technology (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Hematology, Urinalysis), Application (Diabetes, Oncology, Cardiology, Nephrology) - Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.

http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

The global in vitro diagnostics market is projected to reach USD 87.93 Billion by 2023 from USD 68.12 Billion in 2018, at a CAGR of 5.2%.

The rising demand for early and accurate disease diagnosis, increasing prevalence of infectious diseases, increasing adoption of fully-automated instruments and automation in laboratories, increasing adoption of point-of-care testing, and growing awareness of personalized medicine are the key factors driving the growth of the market.

On the basis of technology, the market is broadly divided into immunochemistry/immunoassay, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation & hemostasis, urinalysis, and other technologies. The immunochemistry/immunoassay segment is expected to dominate the market in 2018. The large share of this segment is primarily attributed to the growing preference for these technologies in clinical diagnostics over conventional methods and the ability of immunoassay/immunochemistry technologies to offer faster results with high-sensitivity and accuracy.

On the basis of end user, the market is segmented into laboratories, hospitals, academic institutes, point-of-care testing, patient self-testing, and other end users. The hospitals segment accounted for the largest share of the IVD market in 2017, owing to the large volume of diagnostic tests carried out in hospitals. However, the point-of-care testing segment is estimated to grow at the highest CAGR during the forecast period.

North America is expected to command the largest share of the market in 2018 owing to the availability of government funds, growing use of molecular diagnostics in genetic disorders and cancer screening, and the presence of key players in the region. However, Asia Pacific is expected to register the highest growth rate during the forecast period due to rising healthcare expenditure; increasing number of hospitals and clinical diagnostic laboratories in India and China; increasing incidence of chronic and infectious diseases; rapid development in the healthcare infrastructure of developing countries such as India, China, and South Korea; and increasing per capita income of the middle-class population in the region.

The major factors driving the growth of this market in the North American region include accessibility to advanced technologies, increasing demand for laboratory automation, expansion of molecular diagnostics for genetic disorders and cancer screening, and presence of major leading companies in the US.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights
4.1 In Vitro Diagnostics (IVD) Market Overview
4.2 Asia Pacific: Market, By Product & Service
4.3 Geographic Snapshot of the Market
4.4 Geographic Mix: In Vitro Diagnostics Market
4.5 Market: Developing vs Developed Markets

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Rising Geriatric Population and Subsequent Growth in the Prevalence of Chronic and Infectious Diseases
5.2.1.2 Increasing Adoption of Fully Automated Instruments and Automation in Laboratories
5.2.1.3 Growing Awareness on Personalized Medicine
5.2.1.4 Increasing Adoption of Point-Of-Care Testing
5.2.2 Restraint
5.2.2.1 Unfavorable Reimbursement Scenario
5.2.3 Opportunities
5.2.3.1 Development of Condition-Specific Markers and Tests
5.2.3.2 Growing Significance of Companion Diagnostics
5.2.3.3 Growth Opportunities in Emerging Countries
5.2.4 Challenges
5.2.4.1 Changing Regulatory Landscape
5.2.4.2 Operational Barriers Faced in Conducting Diagnostic Tests

6 Industry Insights
6.1 Introduction
6.2 Industry Trends
6.2.1 Automation of Clinical Laboratory Techniques
6.2.2 Microfluidics-Based Poc and Loc Diagnostic Devices for Laboratory Testing
6.2.3 Rise in Number of Reagent Rental Agreements
6.3 Regulatory Overview
6.3.1 US
6.3.2 Canada
6.3.3 Europe
6.3.4 Japan
6.3.5 China
6.3.6 India
6.3.7 Indonesia
6.3.8 Russia
6.3.9 Saudi Arabia
6.3.10 Mexico
6.3.11 Brazil
6.3.12 South Korea
6.4 Vendor Benchmarking

7 In Vitro Diagnostics Market, By Product & Service
7.1 Introduction
7.2 Reagents & Kits
7.3 Instruments
7.3.1 Fully Automated Instruments
7.3.2 Semi-Automated Instruments
7.3.3 Other Instruments
7.4 Data Management Software
7.5 Services

8 In Vitro Diagnostics Market, By Technology
8.1 Introduction
8.2 Immunoassay/Immunochemistry
8.2.1 Enzyme-Linked Immunosorbent Assay
8.2.1.1 Chemiluminescence Immunoassays
8.2.1.2 Fluorescence Immunoassays
8.2.1.3 Colorimetric Immunoassays
8.2.2 Radioimmunoassay
8.2.3 Rapid Test
8.2.4 Western Blotting
8.2.5 Enzyme-Linked Immunospot Assays
8.3 Clinical Chemistry
8.3.1 Basic Metabolic Panel
8.3.2 Electrolyte Panel
8.3.3 Liver Panel
8.3.4 Lipid Profile
8.3.5 Renal Profile
8.3.6 Thyroid Function Panel
8.3.7 Specialty Chemical Tests
8.4 Molecular Diagnostics
8.4.1 Polymerase Chain Reaction
8.4.2 Isothermal Nucleic Acid Amplification Technology
8.4.3 Microarray
8.4.4 Hybridization
8.4.5 Dna Sequencing & Next-Generation Sequencing
8.4.6 Other Mdx Technologies
8.5 Microbiology
8.6 Hematology
8.7 Coagulation and Hemostasis
8.8 Urinalysis
8.9 Other IVD Technologies

9 In Vitro Diagnostics Market, By Application
9.1 Introduction
9.2 Infectious Diseases
9.3 Diabetes
9.4 Oncology
9.5 Cardiology
9.6 Autoimmune Diseases
9.7 Nephrology
9.8 Drug Testing/Pharmacogenomics
9.9 HIV/Aids
9.10 Other Applications

10 In Vitro Diagnostics Market, By End User
10.1 Introduction
10.2 Hospitals
10.3 Laboratories
10.3.1 Large/Reference Laboratories
10.3.2 Medium-Sized Laboratories
10.3.3 Small Laboratories
10.4 Point-Of-Care Testing
10.5 Patient Self-Testing
10.6 Academic Institutes
10.7 Other End Users

11 In Vitro Diagnostics Market, By Region

12 Competitive Landscape
12.1 Introduction
12.2 Market Share Analysis
12.2.1 Market Share Analysis, By Technology
12.2.1.1 Clinical Chemistry
12.2.1.2 Immunochemistry/Immunoassay
12.2.1.3 Microbiology
12.2.1.4 Molecular Diagnostics
12.2.1.5 Hematology
12.2.1.6 Coagulation
12.3 Competitive Situation and Trends
12.3.1 Product Launches
12.3.2 Agreements, Partnerships, and Collaborations
12.3.3 Acquisitions
12.3.4 Expansions
12.3.5 Other Strategies

13 Company Profiles

    --  Abbott Laboratories, Inc.
    --  Agilent Technologies
    --  Becton, Dickinson and Company
    --  Bio-Rad Laboratories, Inc.
    --  Biomrieux Sa
    --  Danaher Corporation
    --  Diasorin
    --  Johnson & Johnson
    --  Ortho Clinical Diagnostics (A Part of Carlyle Group)
    --  Qiagen
    --  Roche Diagnostics
    --  Siemens AG
    --  Sysmex Corporation
    --  Thermo Fisher Scientific

For more information about this report visit https://www.researchandmarkets.com/research/clp6jj/global_invitro?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-in-vitro-diagnosticsivd-market-2018-2023-increasing-adoption-of-fully-automated-instruments-and-automation-in-laboratories-300636456.html

SOURCE Research and Markets